Compare IMMR & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | CRBU |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.8M | 145.8M |
| IPO Year | 1999 | 2021 |
| Metric | IMMR | CRBU |
|---|---|---|
| Price | $7.25 | $1.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.50 | $10.75 |
| AVG Volume (30 Days) | 336.0K | ★ 1.1M |
| Earning Date | 04-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $35,013,000.00 | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | $44.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $1.25 |
| 52 Week High | $8.05 | $3.53 |
| Indicator | IMMR | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 35.35 |
| Support Level | $6.30 | N/A |
| Resistance Level | $7.82 | $1.72 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 28.47 | 15.79 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.